American States Water Company vs Vertex Pharmaceuticals Incorporated — how do they compare? American States Water Company trades at $87.53 (market cap $3.47B), while Vertex Pharmaceuticals Incorporated trades at $526.84 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 38.7× American States Water Company's market cap, and American States Water Company pays a 2.49% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| AWR | VRTX | |
|---|---|---|
Market Cap | $3.47B | $134.25B |
Sector | Utilities | Health |
52-Week High | $89.28 | $529.65 |
52-Week Low | $70.10 | $376.62 |
Enterprise Value | $4.37B | $128.37B |
Dividend Yield | 2.49% | — |
Signals from Pluang's Aura AI — not financial advice
American States Water (AWR) trades at $87.83, up 1.46% today, with strong technical momentum as moving averages signal bullish alignment. The company maintains robust fundamentals with 20.52% net income margin and consistent dividend growth, recently increasing its quarterly payout by 8.2%. Recent Q2 2026 earnings beat expectations at $1.09 per share, driven by water rate increases and operational gains across business segments.
Outlook remains stable with revenue growth and dividend reliability, though valuation multiples appear elevated versus utilities peers. Key risks include regulatory dependence on rate approvals and competitive pressures. Analyst sentiment is mixed with 20% buy ratings amid concerns about current price levels relative to earnings potential.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Trailing returns across standard periods
Latest headlines on both assets
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →